Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05024695 · ClinicalTrials.gov registry record · NA

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

A NA study of Glaucoma, sponsored by iSTAR Medical.

Active
Registry status
NA
Development phase
975
Enrollment target
20
Study locations

NCT05024695: Active NA study of Glaucoma, sponsored by iSTAR Medical.

NCT05024695 is a NA study of Glaucoma that is active but no longer recruiting, run by iSTAR Medical. The registered enrollment target is 975 participants, roughly in line with the 900-participant average among 92 other Glaucoma trials with a reported enrollment target. The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05024695, a NA study of Glaucoma, is active but no longer recruiting, sponsored by iSTAR Medical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
975 participants
Enrollment target
20
Study locations

Study Summary

Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.

Primary Outcome

Proportion of subjects with ≥ 20% decrease (responders) from Baseline in unmedicated Diurnal IOP at Month 24.

Conditions Studied

Interventions

  • DEVICE MINIject™ Implant

Study Locations (20)

California

  • Beverly Hills Institute of Ophthalmology - Beverly Hills
  • Reeve Woods Eye Center - Chico
  • Sacramento Eye Consultants, A Medical Corporation - Sacramento

Illinois

  • Illinois Eye Center - Peoria
  • Virdi Eye Clinic - Rock Island

Arizona

  • Arizona Advanced Eye Research Institute - Glendale

Arkansas

  • Vold Vision - Fayetteville

Colorado

  • Grand Junction Eye Care - Grand Junction

Florida

  • Eye Associates of Fort Myers - Fort Myers

Idaho

  • Intermountain Eye Center - Eagle

Kansas

  • Stiles Eyecare Excellene and Glaucoma Institute - Overland Park

Trial Details

FieldValue
Enrollment Target 975 participants
Start Date 2021-08-19
Est. Completion 2029-07
Phase NA
iSTAR Medical

1 total trials

What the registry record for NCT05024695 still lists

NCT05024695 is an interventional study that assigns participants to a tested intervention. The registered 975 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 900-participant average among 92 other Glaucoma trials with a reported enrollment target.

The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which MINIject™ Implant is the first listed.

NCT05024695 names 20 study sites across 17 states, led by California, Illinois, Arizona.

Frequently Asked Questions

What is clinical trial NCT05024695 about?

NCT05024695 is a clinical study titled "Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.". Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.

What is the current status of trial NCT05024695?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 975 participants. The study started on 2021-08-19. Estimated completion is 2029-07.

What conditions does trial NCT05024695 study?

This clinical trial studies the following conditions: Glaucoma.

What interventions are being tested in trial NCT05024695?

The interventions under investigation include: MINIject™ Implant (DEVICE).

Who is sponsoring clinical trial NCT05024695?

This trial is sponsored by iSTAR Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05024695 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05024695's enrollment target sits among peer trials

975 5th of 92 higher than 88 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05600777 · 975 participants · Phase 3

    A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

  • NCT06541704 · 975 participants · Phase 3

    A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • NCT06820736 · 975 participants · NA

    A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion

  • NCT07216482 · 975 participants · Phase 3

    A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05024695, the US trial registry maintained by the National Library of Medicine. NCT05024695 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.